Revium Rx. Reiterates Going Concern, Reports $1.5M Cash and Ineffective Controls
RVRC has more than doubled off its 52-week low of $0.3 on light trading volume (0.3× avg).
Summary
Revium Rx.'s Q2 2026 report shows only $1.5 million in cash, a reiterated going concern warning, and ineffective disclosure controls, while its lead drug program advances to Phase 1.
Key Events · Earnings and Guidance · RVRC
-
Going Concern Reiterated
Management states substantial doubt about the company's ability to continue as a going concern, with an accumulated deficit of $26.4 million and no binding commitments for additional capital.
-
Cash Runway Critical
Cash and short-term deposits total approximately $1.5 million as of June 30, 2026, down from $2.7 million at year-end 2025, with net cash used in operations of $1.2 million for the first half.
-
Ineffective Disclosure Controls
The CEO and CFO concluded that disclosure controls and procedures were not effective as of June 30, 2026, indicating ongoing internal control weaknesses.
-
Nano-Mupirocin Phase 1 Approval
The Israeli Ministry of Health granted approval to initiate Phase 1 clinical trials for Nano-Mupirocin in healthy volunteers, a key milestone for the lead program.
Analysis · RVRC · Life Sciences
The quarterly report confirms the company's precarious financial position: $1.5 million in cash against an accumulated deficit of $26.4 million, with no binding commitments for additional capital. Management again states substantial doubt about its ability to continue as a going concern. The disclosure controls and procedures are not effective, adding governance risk. On the operational side, the Nano-Mupirocin program received Israeli Ministry of Health approval to begin Phase 1 trials, a positive step, but the Nano-Candesartan program is stalled by a dispute with Yissum over a scientific report. The recent executive departures—CFO and COO—are also detailed, including a $45 thousand termination benefit and a $111 thousand option modification charge. For a company with a market cap around $101 million, the cash runway is extremely short, and the need for financing is urgent.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RVRC was trading at $1.67 on OTC in the Life Sciences sector, with a market capitalization of approximately $101.4M. The 52-week trading range was $0.30 to $50.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.